Preclinical, non-genetic models of lung adenocarcinoma: a comparative survey

Lung cancer is the leading cause of cancer-related mortality worldwide. Animal models are key in analyzing cancer biology and therapy evaluation. We here compared relevant non-genetic lung cancer models with regard to tumor induction period, incidence, morbidity and mortality rate and the immunological composition of primary tumors and the occurrence of tertiary lymphoid organs (TLO): (I) intraperitoneal Urethane injection (1g/kg), (II) Lewis lung carcinoma (LLC) cell line model (intravenous or subcutaneous), and (III) ex vivo three-dimensional (3D) primary cell culture model established from subcutaneously developed LLC-induced tumors. The incidence of Urethane induced lung tumors was 100% in both, C57BL/6 and BALB/c strains without morbidity or mortality at twenty weeks after injection. The mean size of tumor nodules after Urethane injection was significantly larger in BALB/c mice vs. C57BL/6 (p<0.01). Three times of Urethane injection produced significantly more tumor nodules in both mouse strains compared to one injection (BALB/c: p<0.01; C57BL/6: p<0.05). TLOs were only found in the Urethane-induced model. Although the cell line models also showed 100% induction rate, morbidity was high due to skin ulceration on the inoculation site and the development of pleural effusions in the subcutaneous model and the intravenous model, respectively. Tendencies, but no significant differences (p>0.05) could be found in the count of CD4+, CD8+, F4/80+ and NKp46+ cells in a tumor nodule among investigated models. All discussed models provided a high tumor incidence rate. TLOs were exclusively found in the Urethane-induced model. No significant difference could be found regarding immune cells across models.

[1]  F. López-Ríos,et al.  Treating KRAS-mutant NSCLC: latest evidence and clinical consequences , 2017, Therapeutic advances in medical oncology.

[2]  A. Jager,et al.  Ex vivo tumor culture systems for functional drug testing and therapy response prediction , 2017, Future science OA.

[3]  W. Storkus,et al.  Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO , 2016, Front. Immunol..

[4]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[5]  C. Kemp,et al.  Induction of Lung Tumors in Mice with Urethane. , 2015, Cold Spring Harbor protocols.

[6]  Cameron Alexander,et al.  In vitro co-culture model of medulloblastoma and human neural stem cells for drug delivery assessment. , 2015, Journal of biotechnology.

[7]  Y. Kanai,et al.  Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer , 2015, British Journal of Cancer.

[8]  Georges Noel,et al.  Three-Dimensional Cell Culture: A Breakthrough in Vivo , 2015, International journal of molecular sciences.

[9]  L. weiswald,et al.  Spherical Cancer Models in Tumor Biology1 , 2015, Neoplasia.

[10]  Stefan Przyborski,et al.  Advances in 3D cell culture technologies enabling tissue‐like structures to be created in vitro , 2014, Journal of anatomy.

[11]  W. Peitsch,et al.  Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. , 2014, International journal of clinical and experimental pathology.

[12]  M. Cekanova,et al.  Animal models and therapeutic molecular targets of cancer: utility and limitations , 2014, Drug design, development and therapy.

[13]  Liju Yang,et al.  Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. , 2014, Assay and drug development technologies.

[14]  Wei Sun,et al.  Three-dimensional in vitro cancer models: a short review , 2014, Biofabrication.

[15]  P. Allavena,et al.  Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers , 2014, Clinical Cancer Research.

[16]  J. Tichelaar,et al.  Mouse models of chemically-induced lung carcinogenesis. , 2013, Frontiers in bioscience.

[17]  M. Nevalainen,et al.  Ex vivo prostate cancer explant organ culture model system for targeted drug development in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Hammad,et al.  Tertiary lymphoid organs in infection and autoimmunity , 2012, Trends in Immunology.

[19]  Anne Vincent-Salomon,et al.  Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.

[20]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[21]  Dae-Hun Park,et al.  Diethylnitrosamine (DEN) induces irreversible hepatocellular carcinogenesis through overexpression of G1/S-phase regulatory proteins in rat. , 2009, Toxicology letters.

[22]  A. Richmond,et al.  Mouse xenograft models vs GEM models for human cancer therapeutics , 2008, Disease Models & Mechanisms.

[23]  M. Bibby,et al.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Knuechel,et al.  Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells. , 2004, Cancer letters.

[25]  M. Bibby,et al.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. , 2004, European journal of cancer.

[26]  T. Jacks,et al.  Modeling human lung cancer in mice: similarities and shortcomings , 1999, Oncogene.

[27]  E. Campo,et al.  Ki‐ras gene mutations and absence of p53 gene mutations in spontaneous and urethane‐induced early lung lesions in CBA/J mice , 1998, Molecular carcinogenesis.

[28]  Marshall W. Anderson,et al.  Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Casanova,et al.  Modeling cancer using genetically engineered mice. , 2015, Methods in molecular biology.

[30]  B. Ruggeri,et al.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.

[31]  G. Williams,et al.  N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. , 1996, Pharmacology & therapeutics.